Loading
Latest filing published 01 Dec 2022 for NRX Pharmaceuticals, Inc., €20k. Read the official filing
Daniel C. Javitt (chief executive) discloses dealings in NRX Pharmaceuticals, Inc. to SEC (Form 4). In total, 8 filings cover trades dated from 24 May 2021 to 29 November 2022.
On the market, this insider has only sold: 5 sales, €1.1M in total. Outside the open market, there are 1 share grant. In 2022 alone, the filings show no purchases and 5 sales.
The latest filing, published on 1 December 2022, reports an open-market sale of €20k in NRX Pharmaceuticals, Inc. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
8 of 8 declarations